Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines

Journal of Infectious Diseases

Volumn 210, Issue 6, 2014, Pages 865-874

  Sasaki, Sanae ^a,b   Holmes, Tyson H ^a   Albrecht, Randy A ^c   García Sastre, Adolfo ^c   Dekker, Cornelia L ^a   He, Xiao Song ^a,b   Greenberg, Harry B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; B cell response; Influenza vaccine

Indexed keywords

IMMUNOGLOBULIN A; INACTIVATED INFLUENZA VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; PLASMABLAST DERIVED POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; NORMAL HUMAN; PLASMABLAST RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS NEUTRALIZATION;

ANTIBODY; B-CELL RESPONSE; INFLUENZA VACCINE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CROSS REACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN A; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84906101378     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu190     Document Type: Article

References (45)

1. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and costbenefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655-63.
2. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25:6852-62.
3. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011; 5:67-75.
4. Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011; 29:3633-9.
5. Delem A, Jovanovic D. Correlation between rate of infection and preexisting titer of serum antibody as determined by single radial hemolysis during and epidemic of influenza A/Victoria/3/75. J Infect Dis 1978; 137:194-6.
6. Treanor J,Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Biol 2003; 115:97-104.
7. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine-1978. Rev Infect Dis 1983; 5:723-36.
8. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60.
9. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7.
10. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A metaanalysis. Vaccine 2002; 20:1340-53.
11. Couch RB, Atmar RL, Keitel WA, et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012; 31:190-5.
12. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71.
13. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-28.
14. He XS, Sasaki S, Narvaez CF, et al. Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods 2011; 365:67-75.
15. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011; 121:3109-19.
16. He XS, Sasaki S, Baer J, et al. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis 2013; 207:288-96.
17. Bentebibel SE, Lopez S, Obermoser G, et al. Induction of ICOS-+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5:176ra32.
18. Wang S, Taaffe J, Parker C, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006; 80:11628-37.
19. Golan A, Judge GG, Miller DJ. Maximum entropy econometrics: Robust estimation with limited data. Chichester: John Wiley & Sons, 1996.
20. Yohai VJ. High breakdown-point and high efficiency robust estimates for regression. Ann Statist 1987; 15:642-56.
21. Lee FK, Nahmias AJ, Spira T, et al. Enumeration of human peripheral blood lymphocytes secreting immunoglobulins of major classes and subclasses in healthy children and adults. J Clin Immunol 1991; 11: 213-8.
22. Kantele JM, Kantele A, Arvilommi H. Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors. Clin Exp Immunol 1996; 104:525-30.
23. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza Aviruses. Nat Struct Mol Biol 2009; 16:265-73.
24. Lamere MW, Moquin A, Lee FE, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011; 85:5027-35.
25. el-Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998; 178:933-9.
26. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008; 3:e2975.
27. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66-72.
28. Barria MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013; 207:115-24.
29. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107:18979-84.
30. Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010; 1.
31. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63.
32. García-Cañas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M. Selective and Quantitative Detection of Influenza Virus Proteins in Commercial Vaccines Using Two-Dimensional High-Performance Liquid Chromatography and Fluorescence Detection. Anal Chem 2007; 79:3164-72.
33. Co MDT, Orphin L, Cruz J, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009; 27:319-27.
34. Ann J, Papenburg J, Bouhy X, Rheaume C, Hamelin ME, Boivin G. Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. J Clin Virol 2012; 53:88-92.
35. Corti D, Suguitan AL Jr., Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73.
36. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137-44.
37. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000; 19:S66-71.
38. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
39. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968; 2:778-86.
40. Mozdzanowska K, Maiese K, Furchner M, GerhardW. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999; 254:138-46.
41. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:7381-8.
42. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236:265-75.
43. Ohta R, Torii Y, Imai M, Kimura H, Okada N, Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 2011; 55: 191-8.
44. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cellmediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94.
45. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605